Entering text into the input field will update the search result below

Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy

Jul. 06, 2022 11:48 AM ETAlterity Therapeutics Limited (ATHE) StockBy: Ravikash, SA News Editor

Modern Medicine Research Laboratory: Diverse Team of Multi-Ethnic Young Scientists Passes Samples in Petri Dish. Advanced Lab with High-Tech Equipment, Microbiology Researchers Design, Develop Drugs


  • Alterity Therapeutics (NASDAQ:ATHE) said the first patient was dosed in a a phase 2 trial of ATH434 in Multiple System Atrophy (MSA)
  • MSA is a rare disorder of the nervous system which causes gradual damage to nerve cells in the brain and can affect  breathing, digestion and bladder control.
  • The trial is expected to enroll ~60 adult patients who will either receive one of two doses of ATH434 or placebo for one year.

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About ATHE

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Alterity Therapeutics Limited
BiomX Inc.
Vincerx Pharma, Inc.
Virios Therapeutics, Inc.
Aprea Therapeutics, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.